PD-1 配体在甲状腺上皮性肿瘤中的表达：潜在的临床意义。
PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications.
机构信息
Department of Surgical Sciences, "Sapienza" University of Rome, 00161 Rome, Italy.
Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
出版信息
Int J Mol Sci. 2019 Mar 20;20(6):1405. doi: 10.3390/ijms20061405.
The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to treat. Among these, there are the poorly differentiated and anaplastic thyroid cancers, unresponsive to all the therapies currently in use. In the present review we will summarize information regarding the expression of PD-L1 in the different thyroid cancer histotypes, its correlation with clinicopathological features, and its potential prognostic value. Then, we will evaluate the available data indicating the PD-1/PD-L1 axis as a promising target for thyroid cancer therapy.
针对程序性细胞死亡 1 (PD-1) 受体及其配体 PD-L1 的新型免疫疗法重新燃起了根除最难治疗的人类癌症的希望。其中包括低分化和间变性甲状腺癌，对目前所有使用的疗法均无反应。在本综述中，我们将总结 PD-L1 在不同甲状腺癌组织学类型中的表达、与临床病理特征的相关性及其潜在的预后价值。然后，我们将评估现有数据表明 PD-1/PD-L1 轴作为甲状腺癌治疗的有前途的靶点。
Zotero 插件